Neuropore Therapies Inc. and UCB have formed a worldwide collaboration and agreement to develop and commercialize therapeutic products focused on slowing the progression of Parkinson's disease and related disorders. This includes NPT200-11, Neuropore's small molecule that targets pathogenic alpha-synuclein and which is currently in preclinical development and is expected to enter clinical Phase I development in 2015.

Under the terms of the agreement, UCB will receive the worldwide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase I study is to be initiated in 2015. UCB will lead all further clinical development, regulatory activities and commercialization. Neuropore will receive an initial upfront payment of $20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of $460 million, in addition to royalties on net sales.

Source: UCB